Literature DB >> 28077993

Peroxisome proliferator-activated receptor γ (PPARγ) mediates the protective effect of quercetin against myocardial ischemia-reperfusion injury via suppressing the NF-κB pathway.

Xinyu Liu1, Zhangjie Yu2, Xian Huang3, Yi Gao4, Xiuzhi Wang3, Jianmin Gu1, Song Xue1.   

Abstract

Quercetin plays an important role in myocardial ischemia and reperfusion injury (IRI). However, the underlying mechanism for the protective effect of quercetin is largely unclear. In this study, we explored the protected effects of quercetin against myocardial IRI and its molecular mechanisms. Quercetin, GW9962 (PPARγ antagonist) or PPARγ-siRNA was administered alone or in combination prior to myocardial IRI in mice or to hypoxia and reoxygenation (H/R) treatment in H9C2 cells. Infarct size was evaluated by TTC staining after reperfusion. Myocardial injury was assessed by the serum levels of AST, CK-MB, cardiac troponin T (cTnT) and LDH. Cardiac function was measured by echocardiography. Oxidative stress injury was evaluated by analyses of inducible nitric oxide synthase (iNOS), MDA, SOD and glutathione peroxidase (GSH-PX) levels and by reactive oxygen species (ROS) detection. Myocardium apoptosis was evaluated by TUNEL staining, cleaved caspase-3 and Annexin V/PI detection. Moreover, activation of the NF-κB pathway was reflected by phosphorylation of IκB (p-IκB) and nuclear translocation of NF-κB p65. We reported that pretreatment of quercetin significantly improved cardiac function, diminished myocardial injury and reduced the infarct size. Myocardium oxidative damage and apoptosis were remarkably improved by quercetin treatment in vivo and in vitro. Quercetin also suppressed the activation of the NF-κB pathway induced by myocardial IRI. GW9662 or PPARγ knockdown partially attenuated these cardioprotective effects of quercetin during myocardial IRI. In conclusion, our findings suggest that quercetin ameliorated IRI-induced heart damage via PPARγ activation and the underlying mechanism might involve the inhibition of NF-κB pathway by PPARγ activation.

Entities:  

Keywords:  NF-κB pathway; Quercetin; ischemia-reperfusion injury; myocardium; peroxisome proliferator-activated receptor γ

Year:  2016        PMID: 28077993      PMCID: PMC5209473     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  49 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Role of NF-kappaB on liver cold ischemia-reperfusion injury.

Authors:  Yoshihito Takahashi; Raymond W Ganster; Andrea Gambotto; Lifang Shao; Takashi Kaizu; Tong Wu; Gautam P Yagnik; Atsunori Nakao; George Tsoulfas; Takashi Ishikawa; Toyokazu Okuda; David A Geller; Noriko Murase
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-11       Impact factor: 4.052

Review 3.  The inflammatory response in stroke.

Authors:  Qing Wang; Xian Nan Tang; Midori A Yenari
Journal:  J Neuroimmunol       Date:  2006-12-26       Impact factor: 3.478

4.  Heart protective effects and mechanism of quercetin preconditioning on anti-myocardial ischemia reperfusion (IR) injuries in rats.

Authors:  Hui Liu; Xiaolan Guo; Yi Chu; Shaoping Lu
Journal:  Gene       Date:  2014-04-24       Impact factor: 3.688

Review 5.  Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance.

Authors:  Robin A P Weir; John J V McMurray; Eric J Velazquez
Journal:  Am J Cardiol       Date:  2006-04-21       Impact factor: 2.778

Review 6.  PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.

Authors:  G J Murphy; J C Holder
Journal:  Trends Pharmacol Sci       Date:  2000-12       Impact factor: 14.819

Review 7.  Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury.

Authors:  Costas Giaginis; Gerasimos Tsourouflis; Stamatios Theocharis
Journal:  Curr Mol Med       Date:  2008-09       Impact factor: 2.222

Review 8.  Targeting cell signaling and apoptotic pathways by luteolin: cardioprotective role in rat cardiomyocytes following ischemia/reperfusion.

Authors:  Tongda Xu; Dongye Li; Dehua Jiang
Journal:  Nutrients       Date:  2012-12-12       Impact factor: 5.717

9.  Quercetin prevents left ventricular hypertrophy in the Apo E knockout mouse.

Authors:  Elena Ulasova; Jessica Perez; Bradford G Hill; Wayne E Bradley; David W Garber; Aimee Landar; Stephen Barnes; Jeevan Prasain; Dale A Parks; Louis J Dell'Italia; Victor M Darley-Usmar
Journal:  Redox Biol       Date:  2013-07-16       Impact factor: 11.799

10.  Hesperidin produces cardioprotective activity via PPAR-γ pathway in ischemic heart disease model in diabetic rats.

Authors:  Yogeeta O Agrawal; Pankaj Kumar Sharma; Birendra Shrivastava; Shreesh Ojha; Harshita M Upadhya; Dharamvir Singh Arya; Sameer N Goyal
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

View more
  29 in total

1.  Inhibition of nuclear factor kappa B pathway protects myocardial ischemia/reperfusion injury in rats under treatment with abnormal savda munziq.

Authors:  Abudunaibi Maimaitiaili; Junhong Li; Aili Aibibula; Mulati Abudureheman
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

2.  Effects of Quercetin on Cardiac Function in Pressure Overload and Postischemic Cardiac Injury in Rodents: a Systematic Review and Meta-Analysis.

Authors:  Hawa Nordin Siti; Juriyati Jalil; Ahmad Yusof Asmadi; Yusof Kamisah
Journal:  Cardiovasc Drugs Ther       Date:  2020-10-16       Impact factor: 3.727

3.  A Systematic Review and Meta-Analysis of Phytoestrogen Protects Against Myocardial Ischemia/Reperfusion Injury: Pre-Clinical Evidence From Small Animal Studies.

Authors:  Yumeng Wang; Xintian Shou; Zongjing Fan; Jie Cui; Donghua Xue; Yang Wu
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

4.  The induced RNA-binding protein, HuR, targets 3'-UTR region of IL-6 mRNA and enhances its stabilization in periodontitis.

Authors:  K Ouhara; S Munenaga; M Kajiya; K Takeda; S Matsuda; Y Sato; Y Hamamoto; T Iwata; S Yamasaki; K Akutagawa; N Mizuno; T Fujita; E Sugiyama; H Kurihara
Journal:  Clin Exp Immunol       Date:  2018-03-08       Impact factor: 4.330

5.  Inactivated pseudomonas aeruginosa protects against myocardial ischemia reperfusion injury via Nrf2 and HO-1.

Authors:  Zhigang Zhao; Zhongzhi Tang; Wenkai Zhang; Jie Liu; Bo Li; Shifang Ding
Journal:  Exp Ther Med       Date:  2020-03-17       Impact factor: 2.447

6.  Verapamil suppresses cardiac alternans and ventricular arrhythmias in acute myocardial ischemia via ryanodine receptor inhibition.

Authors:  Yu-Lei Deng; Jun-Yan Zhao; Ji-Hua Yao; Qiang Tang; Le Zhang; Hong-Lian Zhou; Cun-Tai Zhang; Jia-Gao Lv; Xiao-Qing Quan
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

Review 7.  Therapeutic potential of IKK-β inhibitors from natural phenolics for inflammation in cardiovascular diseases.

Authors:  Peng Zhou; Fang Hua; Xiang Wang; Jin-Ling Huang
Journal:  Inflammopharmacology       Date:  2020-01-01       Impact factor: 4.473

8.  Luteolin, quercetin, genistein and quercetagetin inhibit the effects of lipopolysaccharide obtained from Porphyromonas gingivalis in H9c2 cardiomyoblasts.

Authors:  Gloria Gutiérrez-Venegas; Alfredo Torras-Ceballos; Juan Arturo Gómez-Mora; Berenice Fernández-Rojas
Journal:  Cell Mol Biol Lett       Date:  2017-09-04       Impact factor: 5.787

9.  Effect of Hexadecyl Azelaoyl Phosphatidylcholine on Cardiomyocyte Apoptosis in Myocardial Ischemia-Reperfusion Injury: A Hypothesis.

Authors:  Limin Feng; Wennan Liu; Jianzhou Yang; Qing Wang; Shiwu Wen
Journal:  Med Sci Monit       Date:  2018-04-30

10.  Flavonoids as Putative Inducers of the Transcription Factors Nrf2, FoxO, and PPARγ.

Authors:  Kathrin Pallauf; Nils Duckstein; Mario Hasler; Lars-Oliver Klotz; Gerald Rimbach
Journal:  Oxid Med Cell Longev       Date:  2017-07-06       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.